|
 |
Glucacon-like Peptide - 1 (GLP-1)
Glucagon-like peptide-1 (GLP-1) is an endogenous peptide with many important physiological actions including
stimulation of insulin release from the pancreas. Furthermore, GLP-1 reduces the gastrointestinal motor
activity and increases the compliance of the gastric ventricle wall. By modulating smooth muscle contraction within the gut, GLP-1 has been shown to reduce contractions and muscular spasm associated with an IBS attack .
ROSE-010 a Patented Stable Analogue of GLP-1
Native GLP-1 is rapidly cleared from the circulation. ROSE-010 is a stable analogue of GLP-1 and has a
circulatory half life of about 1 hour. It was originally called LY307161 and was licensed from Eli Lilly who
had originally developed it for a diabetes indication.
ROSE-010 in Irritable Bowel Syndrome
The original clinical concept for GLP-1 therapy in IBS was developed by Prof Per Hellstrom at the Karolinska
Institute, Sweden.
Clinical Studies with ROSE-010
We are developing ROSE-010 as a treatment for severe pain attacks in IBS and FD. In a Phase IIa prospective,
randomized, placebo-controlled trial in IBS we have shown that ROSE-010 significantly reduces pain in severe
attacks and does so within a clinically
meaningful time period.
A dose and pharmacodynamic study is currently in progress at the Mayo Clinic (Rochester, USA) with Prof Michael Camilleri. Further details can be found at the link below. Phase IIb study is planned based on the latest FDA guidance on IBS pain measurement.
http://www.clinicaltrials.gov/ct2/show/NCT01056107?term=rose-010&rank=1
|
